• Something wrong with this record ?

Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma

I. Richter, TJECJBTBJ. Dvorak,

. 2019 ; 24 (5) : 2155-2160. [pub] -

Language English Country Greece

Document type Journal Article

PURPOSE: To detect the expression of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma (MCC) and to determine the prognostic influence of the PD-L1 expression. METHODS: A total of 13 patients with MCC were retrospectively evaluated (12 patients with primary skin lesion, one patient was diagnosed as unknown primary MCC). All patients underwent surgical resection. PD-L1 was determinated by imunohistochemistry. Immunostaining results were evaluated semiquantitatively. The prognostic influence of the expression of PD-L1 on overall survival (OS) was calculated with the Kaplan-Meier method and log-rank test. RESULTS: PD-L1 positivity was detected in 8 patients (61.5%), in all cases the result was 1+. PD-L1 negativity was shown in the remaining 5 patients. In patients with PD-L1 positivity median OS was 42.1 months (95% CI 9.3-42.1) compared with median OS of 9.4 months (95% CI 2.1-80.9) in the group of patients without PD-L1 positivity (p=0.417). CONCLUSIONS: PD-L1 positivity was found in 61.5% of patients with MCC. No prognostic significance of PD-L1 expression for OS was demonstrated.

000      
00000naa a2200000 a 4500
001      
bmc20023703
003      
CZ-PrNML
005      
20201214130903.0
007      
ta
008      
201125s2019 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)31786889
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Richter, Igor $u Department of Oncology, Regional Hospital Liberec, Czech Republic.
245    10
$a Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma / $c I. Richter, TJECJBTBJ. Dvorak,
520    9_
$a PURPOSE: To detect the expression of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma (MCC) and to determine the prognostic influence of the PD-L1 expression. METHODS: A total of 13 patients with MCC were retrospectively evaluated (12 patients with primary skin lesion, one patient was diagnosed as unknown primary MCC). All patients underwent surgical resection. PD-L1 was determinated by imunohistochemistry. Immunostaining results were evaluated semiquantitatively. The prognostic influence of the expression of PD-L1 on overall survival (OS) was calculated with the Kaplan-Meier method and log-rank test. RESULTS: PD-L1 positivity was detected in 8 patients (61.5%), in all cases the result was 1+. PD-L1 negativity was shown in the remaining 5 patients. In patients with PD-L1 positivity median OS was 42.1 months (95% CI 9.3-42.1) compared with median OS of 9.4 months (95% CI 2.1-80.9) in the group of patients without PD-L1 positivity (p=0.417). CONCLUSIONS: PD-L1 positivity was found in 61.5% of patients with MCC. No prognostic significance of PD-L1 expression for OS was demonstrated.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antigeny CD274 $x genetika $7 D060890
650    _2
$a Merkelův nádor $x diagnóza $x diagnostické zobrazování $x genetika $x patologie $7 D015266
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $x genetika $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    12
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dvorak, Tomas Jirasek Eva Cermakova Jiri Bartos Tomas Büchler Josef
773    0_
$w MED00005361 $t Journal of B.U.ON. : official journal of the Balkan Union of Oncology $x 2241-6293 $g Roč. 24, č. 5 (2019), s. 2155-2160
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31786889 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130902 $b ABA008
999    __
$a ok $b bmc $g 1596022 $s 1114379
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 24 $c 5 $d 2155-2160 $e - $i 2241-6293 $m Journal of Balkan Union of Oncology $n J BUON $x MED00005361
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...